Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/acn3.51282 http://scihub22266oqcxt.onion/10.1002/acn3.51282 33369288!7886031!33369288     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Ann+Clin+Transl+Neurol 2021 ; 8 (2): 385-394 Nephropedia Template TP {{tp|p=33369288|t=2021. Real-world experience of ocrelizumab in multiple sclerosis in a Spanish population |pdf=|usr=}}{{33369288}} gab.com Text Real-world experience of ocrelizumab in multiple sclerosis in a Spanish population JO: Ann Clin Transl Neurol http://www.kidney.de/pget.php?&tw=1&pmid=33369288 #FOAvip OBJECTIVE: Pivotal trial have shown that patients with multiple sclerosis (MS) receiving ocrelizumab had better outcomes. However, data on ocrelizumab in clinical practice are limited. The aim of this study was to evaluate the preliminary safety profile and effectiveness of ocrelizumab treatment for multiple sclerosis (MS) in a real-world clinical setting. METHODS: We conducted a retrospective study including consecutive patients from nine public hospitals in south-eastern Spain who received ocrelizumab after it was approved. RESULTS: A total of 228 MS patients were included (144 with relapsing-remitting MS [RRMS], 25 secondary progressive MS [SPMS], and 59 primary progressive MS [PPMS]). Median follow-up period was 12 months (range, 1-32). No evidence of disease activity (NEDA) status at year 1 was achieved in 91.2% of the relapsing MS (RMS) population, while disability progression was detected in 37.5% of the PPMS patients (median follow-up period, 19 months). The most common adverse events reported were infusion-related reactions and infections, with the most common infections being urinary tract infections followed by upper respiratory infections and COVID-19. INTERPRETATION: The preliminary results in our real-world setting show that ocrelizumab presented excellent results in suppressing disease activity with a favorable and consistent safety profile. Twit Text FOAVip Real-world experience of ocrelizumab in multiple sclerosis in a Spanish population ????Ann Clin Transl Neurol http://www.kidney.de/pget.php?&tw=1&pmid=33369288 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33369288 #FOAvip English Wikipedia <ref>{{Cite pmid|33369288}}</ref> Real-world experience of ocrelizumab in multiple sclerosis in a Spanish population #MMPMID33369288 Fernandez-Diaz E; Perez-Vicente JA; Villaverde-Gonzalez R; Berenguer-Ruiz L; Candeliere Merlicco A; Martinez-Navarro ML; Gracia Gil J; Romero-Sanchez CM; Alfaro-Saez A; Diaz I; Gimenez-Martinez J; Mendez-Miralles MA; Millan-Pascual J; Jimenez-Pancho J; Mola S; Sempere AP Ann Clin Transl Neurol 2021[Feb]; 8 (2): 385-394 PMID33369288show ga OBJECTIVE: Pivotal trial have shown that patients with multiple sclerosis (MS) receiving ocrelizumab had better outcomes. However, data on ocrelizumab in clinical practice are limited. The aim of this study was to evaluate the preliminary safety profile and effectiveness of ocrelizumab treatment for multiple sclerosis (MS) in a real-world clinical setting. METHODS: We conducted a retrospective study including consecutive patients from nine public hospitals in south-eastern Spain who received ocrelizumab after it was approved. RESULTS: A total of 228 MS patients were included (144 with relapsing-remitting MS [RRMS], 25 secondary progressive MS [SPMS], and 59 primary progressive MS [PPMS]). Median follow-up period was 12 months (range, 1-32). No evidence of disease activity (NEDA) status at year 1 was achieved in 91.2% of the relapsing MS (RMS) population, while disability progression was detected in 37.5% of the PPMS patients (median follow-up period, 19 months). The most common adverse events reported were infusion-related reactions and infections, with the most common infections being urinary tract infections followed by upper respiratory infections and COVID-19. INTERPRETATION: The preliminary results in our real-world setting show that ocrelizumab presented excellent results in suppressing disease activity with a favorable and consistent safety profile. |Adult[MESH] |Antibodies, Monoclonal, Humanized/*therapeutic use[MESH] |Brain/diagnostic imaging[MESH] |Disease Progression[MESH] |Female[MESH] |Humans[MESH] |Immunologic Factors/*therapeutic use[MESH] |Injection Site Reaction[MESH] |Magnetic Resonance Imaging[MESH] |Male[MESH] |Middle Aged[MESH] |Multiple Sclerosis, Chronic Progressive/diagnostic imaging/*drug therapy/physiopathology[MESH] |Multiple Sclerosis, Relapsing-Remitting/diagnostic imaging/*drug therapy/physiopathology[MESH] |Retrospective Studies[MESH] |Spain[MESH] |Spinal Cord/diagnostic imaging[MESH]Real-world experience of ocrelizumab in multiple sclerosis in a Spanis(epmc).pdf DeepDyve Pubget Overpricing